Philadelphia, Pennsylvania--(Newsfile Corp. - October 8, 2024) - Current Inari Medical, Inc. (NASDAQ: NARI) shareholders who have held shares of the Company's stock since prior to February 24, 2022, can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award if appropriate, at no cost to them whatsoever. Click here to learn more: https://grabarlaw.com/the-latest/inari-shareholder-investigation/.
WHY: An underlying securities fraud class action complaint alleges that certain officers and directors of Inari consistently touted Inari's "record revenue," purportedly driven by "the strength in our core VTE business" while failing to disclose that a significant portion of its expenses were used to compensate medical professionals improperly for using Inari's products. The complaint further alleges that the Company was being investigated by the U.S. Department of Justice for unlawfully compensating health care professionals in violation of the federal Anti-Kickback Statute and Civil False Claims Act and had misled investors regarding business expenses in order to conceal their illicit conduct.
WHAT TO DO NOW:If you have held Inari shares since prior to February 24, 2022 and would like to learn more at no cost to you, you are encouraged to visit https://grabarlaw.com/the-latest/inari-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com or Mia Heller at mheller@grabarlaw.com, or call us at 267-507-6085.
Attorney Advertising Disclaimer
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/225978
